ERBB2 and breast carcinoma: The emergence of anti-HER-2 therapy has dramatically improved the prognosis of HER-2 + patients, ranging from monoclonal antibodies26、small molecule targeted drugs to antibody-drug conjugates27which have improved the pathologic complete response rate and long-term efficacy and have continuously rewritten the treatment landscape of HER-2 + advanced breast cancer treatment landscape.